natgillin/translations-raw huggingface dataset:
If you want more information on the basis of the CHMP recommendations, read the Scientific Discussion (also part of the EPAR).
Kui soovite lisateavet inimravimite komitee soovituste aluse kohta, lugege palun teadusliku arutelu kokkuvõtet (samuti Euroopa avaliku hindamisaruande osa)
When an infant is given the vaccine, the immune system recognises the parts of the bacteria and viruses as ‘foreign' and makes antibodies against them.
Kui väikelapsele manustatakse vaktsiini, siis identifitseerib immuunsüsteem bakterite ja viiruste osad kui võõrkehad ja tekitab nende vastu antikehi.
Quintanrix contains small amounts of:
Quintanrix sisaldab väheses koguses järgmisi koostisosi:
Vaccines work by ‘teaching' the immune system (the body's natural defences) how to defend itself against diseases.
Vaktsiin õpetab immuunsüsteemi (organismi kehaomane kaitsemehhanism) end haiguste vastu kaitsma.
The vaccine is given by deep injection into a muscle, preferably the thigh.
Vaktsiin manustatakse sügava lihasesisese süstena, eelistatult reide.
It should not be given if the child has had encephalopathy (a brain disease) of unknown cause within seven days of a previous vaccination with a vaccine containing pertussis.
Vaktsiini ei tohi manustada lapsele, kellel seitsme päeva jooksul pärast eelnevat läkaköha sisaldava vaktsiiniga vaktsineerimist esines teadmata põhjustel entsefalopaatia (ajuhaigus).
The recommended vaccination schedule for Quintanrix is three doses, given at intervals of at least four weeks within the first six months of life.
Soovitatav Quintanrixi vaktsineerimisskeem näeb ette kolme annuse manustamist vähemalt neljanädalaste ajavahemike järel esimese kuue elukuu vältel.
These active substances were also available in other vaccines before that date.
Enne seda on ravimi toimeained olnud kasutusel ka muudes vaktsiinides.
In three studies, the effects of Quintarix were compared with those of the combination of Tritanrix HepB and a vaccine containing Hib: two of these studies involved a total of 1,208 infants who were vaccinated at two, four and six months of age and one involved 294 infants vaccinated at three, four and five months of age.
Kolmes uuringus võrreldi Quintanrixi toimet vaktsiini Tritanrix HepB ja Hib-bakterit sisaldava vaktsiini kombineeritud toimega: kahes uuringus osales 1208 väikelast, keda vaktsineeriti kahe, nelja ja kuue kuu vanuselt; ühes uuringus osales 294 väikelast, keda vaktsineeriti kolme, nelja ja viie kuu vanuselt.
The fifth study looked at the effects of a fourth, booster dose of Quintanrix in the second year of life in 357 infants.
Viiendas uuringus hinnati teisel eluaastal manustatud Quintanrixi neljanda revaktsineerimisannuse tõhusust 357 väikelapsel.
Quintarix was as effective as the two separate vaccines at producing protective levels of antibodies.
Quintarix oli antikehade kaitsval tasemel tekkimise poolest sama tõhus kui kaks eraldi manustatud vaktsiini.
The surface antigens of the hepatitis B virus are produced by a method known as ‘recombinant DNA technology': they are made by a yeast that has received a gene (DNA), which makes it able to produce the proteins.
B-hepatiidi pinnaantigeene toodetakse rekombinantDNA-tehnika meetodil: neid toodab pärm, millesse on viidud valkude teket võimaldav geen (DNA).
The most common side effects with Quintanrix (seen in more than 1 in 10 doses of the vaccine) are irritability, drowsiness, loss of appetite, pain, redness and swelling, and fever.
Quintanrixi kõige sagedamad kõrvalnähud (esinenud enam kui ühe annuse korral kümnest) olid kergesti ärrituvus, uimasus, isutus, valu, punetus, turse ja palavik.
The first dose can be administered at six weeks of age.
Esimese annuse võib manustada kuuenädalasele imikule.
The fourth study compared the effects of Quintarix given at six, 10 and 14 weeks of age in 318 infants who either had or had not received a hepatitis B vaccine at birth.
Neljandas uuringus võrreldi 6., 10. ja 14. elunädalal manustatud Quintanrixi toimet 318 väikelapsele, keda pärast sündimist oli või ei olnud vaktsineeritud B-hepatiidi vastu.
Quintanrix is a vaccine.
Quintanrix on vaktsiin.
The study of booster vaccination also showed Quintanrix was as effective as the two separate vaccines, with between 92 and 100% of the infants having protective levels of antibodies 42 days after the booster vaccination.
Ka revaktsineerimise uuring näitas, et Quintanrix oli niisama tõhus kui kaks eraldi manustatud vaktsiini: 42 päeva pärast vaktsiini manustamist oli 92-100% väikelastel kaitsval tasemel antikehi.
It contains the following active substances: toxoids (chemically weakened toxins) from diphtheria and tetanus, inactivated (killed) Bordetella pertussis (a bacterium that causes whooping cough), parts of the hepatitis B virus and polysaccharides (sugars) from the bacterium Haemophilus influenzae type b (‘Hib', a bacterium that causes meningitis).
See sisaldab järgmisi toimeaineid: difteeria ja teetanuse toksoidid (keemiliselt nõrgestatud toksiinid), inaktiveeritud (surmatud) Bordetella pertussis (läkaköha põhjustav bakter), B-hepatiidi viiruse osad ja B-tüüpi Haemophilus influenzae bakteri (meningiiti põhjustav Hib-bakter).
Quintanrix can be given to children who received a hepatitis B vaccine at birth.
Quintanrixi võib manustada ka lastele, kellele kohe pärast sündi on manustatud B-hepatiidi vaktsiini.
Quintanrix is a vaccine, which is available as a powder and suspension to be made up into a suspension for injection.
Quintanrix on vaktsiin, mida turustatakse pulbri ja suspensioonina, et valmistada sellest süstesuspensioon.
For the full list of side effects reported with Quintanrix, see the Package Leaflet.
Quintanrixi kohta teatatud kõrvalnähtude täieliku loetelu leiate pakendi infolehelt.
What is Quintanrix?
Mis on Quintanrix?
• ‘surface antigen' (proteins from the surface) of the hepatitis B virus.
• B-hepatiidi viiruse pinnaantigeenid (pinnavalgud).
EUROPEAN PUBLIC ASSESSMENT REPORT (EPAR) QUINTANRIX EPAR summary for the public
QUINTANRIX Kokkuvõte üldsusele
As for all vaccines, if Quintanrix is used in very premature babies, there is a risk of the babies experiencing apnoea (brief pauses in breathing).
Nagu kõigi vaktsiinide puhul, võib ka Quintanrixi manustamisel sügavalt enneaegsetele lastele tekkida apnoe (lühiaegne hingamispeetus).
Why has Quintanrix been approved?
Miks Quintanrix heaks kiideti?
The active substances in Quintanrix have been available in the European Union (EU) for a number of years in other vaccines: diphtheria, tetanus, pertussis and hepatitis B, has been available in Tritanrix HepB since 1996.
Quintanrixi toimeained on olnud pikka aega Euroopa Liidus kasutusel selliste haiguste nagu difteeria, teetanuse, läkaköha ja B-hepatiidi vaktsiinides; Tritanrix HepB koostises need olnud alates 1996. aastast.
The full EPAR for Quintanrix can be found here.
Euroopa avaliku hindamisaruande täisteksti Quintanrixi kohta leiate siit.
Other information about Quintanrix:
Muu teave Quintanrixi kohta
What is the risk associated with Quintanrix?
Mis riskid Quintanrixiga kaasnevad?
• toxoids from the bacteria that cause diphtheria and tetanus;
• difteeriat ja teetanust põhjustavate bakterite toksoidid;
Quintanrix can also be used to boost previous vaccinations against diphtheria, tetanus and pertussis, against hepatitis B or against Hib, when it should be given at least six months after the last dose of the first vaccination course.
Quintanrixi võib kasutada ka varasemate difteeria, teetanuse, läkaköha, Bhepatiidi ja Hib-bakteri vastaste vaktsineerimistega saavutatud immuunsuse tugevdamiseks, andes vaktsiini, kui esimese vaktsineerimiskuuri viimase annuse manustamisest on möödunud kuus kuud.
Quintanrix is used to vaccinate infants under one year of age against diphtheria, tetanus, pertussis (whooping cough), hepatitis B and ‘invasive' diseases caused by Hib (such as bacterial meningitis).
Quintanrixi kasutatakse alla 1-aastaste väikelaste vaktsineerimiseks difteeria, teetanuse, läkaköha, B-hepatiidi ja Hib-bakteri poolt põhjustatud invasiivsete haiguste (nagu bakteriaalne meningiit) vastu.
The Committee for Medicinal Products for Human Use (CHMP) decided that Quintanrix's benefits are greater than its risks for primary immunisation of infants (during the first year of life) against diphtheria, tetanus, pertussis, hepatitis B and invasive disease caused by Hib and for booster immunisation of young children during the second year of life.
Inimravimite komitee jõudis otsusele, et Quintanrixi kasulikkus väikelaste immuniseerimiseks (nende esimesel eluaastal) difteeria, teetanuse, läkaköha, B-hepatiidi ja Hib-bakteri ja invasiivse haiguse vastu ning juba saavutatud immuunsuse tugevdamiseks on suurem kui vaktsineerimisega kaasnevad võimalikud riskid.
How does Quintanrix work?
Kuidas Quintanrix toimib?
Overall, between 95 and 100% of the infants had protective levels of antibodies to diphtheria, tetanus, pertussis, hepatitis B and Hib, one month after the first vaccination course.
Üks kuu pärast vaktsineerimiskuuri oli 95-100% väikelastest difteeria, teetanuse, läkaköha, B-hepatiidi ja Hib-bakteri vastaseid antikehi kaitsval tasemel.
What benefit has Quintanrix shown during the studies?
Milles seisneb uuringute põhjal Quintanrixi kasulikkus?
• polysaccharides extracted from the ‘capsules' that surround the bacterium Hib - the polysaccharides are chemically attached (conjugated) to tetanus toxoid as a carrier protein because this improves the response to the vaccine;
(konjugeeritud) teetanuse toksoidide kui kandjavalguga, sest see parandab reageerimist vaktsiinile;
• killed whole B. pertussis;
• surmatud Bordetella pertussise bakterid;
What is Quintanrix used for?
Milleks Quintanrixi kasutatakse?
How has Quintanrix been studied?
Kuidas Quintanrixi uuriti?
After the first vaccination course, a booster should be given, preferably before the end of the second year of life.
Pärast esimest vaktsineerimiskuuri tuleb väikelapsed teisel eluaastal revaktsineerida, et tugevdada juba tekkinud immuunsust.
How is Quintanrix used?
Kuidas Quintanrixi kasutatakse?
Quintanrix should be postponed in people with a severe sudden fever.
Äkki tekkiva kõrge palaviku korral tuleb Quintanrixi manustamine edasi lükata.
The vaccine is ‘adsorbed'.
Quintanrix on adsorbeeritud vaktsiin.
EMA/553501/2018 EMEA/H/C/004710
EMA/553501/2018 EMA/H/C/004710
Further information on Deferiprone Lipomed can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Lisateave ravimi Deferiprone Lipomed kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Over time, the excess iron can damage important organs such as the heart or liver.
Liigne raud võib aja jooksul kahjustada tähtsaid elundeid, näiteks südant või maksa.
This helps to correct the iron overload and prevent damage due to excess iron.
See aitab korrigeerida raualiigsust ja ennetada liigsest rauast põhjustatud kahjustusi.
Doses above 100 mg/kg a day are not recommended because of a potentially increased risk of side effects.
Annused üle 100 mg/kg ööpäevas ei ole soovitatavad, sest kõrvalnähtude risk võib olla suurem.
Deferiprone Lipomed (deferiprone)
Deferiprone Lipomed (deferiproon)
What measures are being taken to ensure the safe and effective use of Deferiprone Lipomed?
Mis meetmed võetakse, et tagada ravimi Deferiprone Lipomed ohutu ja efektiivne kasutamine?
Two medicines are bioequivalent when they produce the same levels of the active substance in the body and are therefore expected to have the same effect.
Kaks ravimit on bioekvivalentsed, kui mõlemad ravimid tekitavad organismis sama toimeainesisalduse ja seetõttu on eeldatav toime ühesugune.
The company also carried out a study that showed that it is ‘bioequivalent' to the reference medicine.
Ettevõte tegi ka uuringu, mis näitas, et see on bioekvivalentne võrdlusravimiga.
The doctor may interrupt treatment if iron levels in the body get too low.
Arst võib ravi katkestada, kui organismi rauasisaldus muutub liiga väikeseks.
However, the body does not have a natural way of removing excess iron, so it builds up.
Organismil puudub aga looduslik võime liigset rauda eemaldada, mistõttu see koguneb organismis.
• in combination with another iron chelator, when treatment with one iron chelator on its own is ineffective or when prevention or treatment of life-threatening conditions requires rapid or intensive correction of iron levels.
• kombinatsioonis teise rauda kelaativa ainega, kui ühe rauda kelaativa aine kasutamisest ei piisa või kui eluohtlike haigusseisundite ennetamiseks või raviks tuleb rauasisaldust kiiresti või efektiivselt korrigeerida.
The usual dose of Deferiprone Lipomed is 75 mg per kilogram body weight each day, divided into three separate doses.
Ravimi Deferiprone Lipomed tavaannus on 75 mg kehakaalu kilogrammi kohta ööpäevas jagatuna kolmeks annuseks.
What is Deferiprone Lipomed and what is it used for?
Mis on Deferiprone Lipomed ja milleks seda kasutatakse?
The European Medicines Agency concluded that, in accordance with EU requirements, Deferiprone Lipomed has been shown to have comparable quality and to be bioequivalent to Ferriprox.
Euroopa Ravimiamet järeldas, et vastavalt ELi nõuetele on tõendatud ravimi Deferiprone Lipomed võrreldav kvaliteet ja bioekvivalentsus ravimiga Ferriprox.
Side effects reported with Deferiprone Lipomed are carefully evaluated and any necessary action taken to protect patients.
Ravimi Deferiprone Lipomed kõrvaltoimeid hinnatakse hoolikalt ja patsientide kaitseks rakendatakse vajalikke meetmeid.
Patients with thalassaemia major need frequent blood transfusions.
Raske talasseemiaga patsiendid vajavad sagedasi vereülekandeid.
Because Deferiprone Lipomed is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.
Et Deferiprone Lipomed on geneeriline ravim ja võrdlusravimiga bioekvivalentne, peetakse tema kasulikkust ja riske samadeks mis võrdlusravimil.
This means that Deferiprone Lipomed contains the same active substance and works in the same way as a ‘reference medicine' already authorised in the EU called Ferriprox.
See tähendab, et Deferiprone Lipomed sisaldab sama toimeainet ja toimib samamoodi nagu võrdlusravim Ferriprox, millel juba on ELis müügiluba.
As for every medicine, the company provided studies on the quality of Deferiprone Lipomed.
Nagu iga ravimi korral, esitas ettevõte ravimi Deferiprone Lipomed kvaliteedi uuringud.
It attaches to iron in the body to form a compound that can be excreted by the body, mainly in the urine, and to a lesser extent in the stools.
See seondub organismis rauaga, moodustades ühendi, mis eritub organismist - põhiliselt uriiniga ja vähemal määral roojaga.
Deferiprone Lipomed is available as 500 mg tablets to be taken by mouth.
Ravimit Deferiprone Lipomed turustatakse 500 mg suukaudsete tablettidena.
As for all medicines, data on the use of Deferiprone Lipomed are continuously monitored.
Nagu kõigi ravimite puhul, teostatakse ravimi Deferiprone Lipomed kasutamise kohta pidevat järelevalvet.
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Deferiprone Lipomed have also been included in the summary of product characteristics and the package leaflet.
Ravimi Deferiprone Lipomed ohutu ja efektiivse kasutamise soovitused ja ettevaatusmeetmed tervishoiutöötajatele ja patsientidele on samuti lisatud ravimi omaduste kokkuvõttesse ja pakendi infolehele.
The company that markets Deferiprone Lipomed will ensure that patients taking the medicine, or their carers, are provided with a reminder card with information on how to take the medicine safely.
Ravimi Deferiprone Lipomed turustaja annab ravimit kasutavatele patsientidele või nende hooldajatele meelespea ravimi ohutu kasutamise teabega.
Studies on the benefits and risks of the active substance in the authorised uses have already been carried out with the reference medicine, Ferriprox, and do not need to be repeated for Deferiprone Lipomed.
Võrdlusravimiga Ferriprox on juba tehtud toimeaine heakskiidetud kasutamisviiside kasulikkuse ja riski uuringud ning neid ei ole vaja ravimiga Deferiprone Lipomed korrata.
• on its own, when standard iron chelator treatment cannot be used or is inadequate;
• ainuravimina, kui raua kelaatijaga tehtav tavaravi on vastunäidustatud või ebapiisav;
Therefore, the Agency's view was that, as for Ferriprox, the benefit of Deferiprone Lipomed outweighs the identified risk and it can be authorised for use in the EU.
Seetõttu on amet arvamusel, et nagu ka Ferriproxi korral, ületab ravimi Deferiprone Lipomed kasulikkus sellega kaasnevad riskid ja seda võib kasutada ELis.
For more information about using Deferiprone Lipomed, see the package leaflet or contact your doctor or pharmacist.
Lisateavet ravimi Deferiprone Lipomed kasutamise kohta vt pakendi infolehest või konsulteeri oma arsti või apteekriga.
Deferiprone Lipomed is an ‘iron chelator' (a substance that attaches to iron) that is used to treat iron overload (an excess of iron in the body) in patients with thalassaemia major.
Deferiprone Lipomed on raua kelaatija (st rauaga seonduv aine), mida kasutatakse raualiigsuse (organismi liigse rauasisalduse) raviks raske talasseemiaga patsientidel.
Deferiprone Lipomed contains the active substance deferiprone and is a ‘generic medicine'.
Deferiprone Lipomed sisaldab toimeainena deferiprooni ja on geneeriline ravim.
This is an inherited disease in which patients are unable to make enough haemoglobin, the protein found in red blood cells that carries oxygen around the body.
Talasseemia on pärilik haigus, mille korral patsiendil ei teki piisavalt hemoglobiini (punavereliblede valk, mis kannab hapnikku organismis laiali).
The doctor may adjust the dose of Deferiprone Lipomed depending on the patient's response, which should be measured every two to three months with blood tests.
Ravivastust tuleb hinnata vereanalüüside põhjal iga 2-3 kuu järel.
An overview of Deferiprone Lipomed and why it is authorised in the EU
Ülevaade ravimist Deferiprone Lipomed ja ELis müügiloa väljastamise põhjendus
Other information about Deferiprone Lipomed
Muu teave ravimi Deferiprone Lipomed kohta
When patients receive repeated transfusions, the transfused red cells bring iron into the body.
Korduvate vereülekannetega lisatakse patsiendi organismi ülekantavate vererakkudega rauda.
How does Deferiprone Lipomed work?
Kuidas Deferiprone Lipomed toimib?
Deferiprone Lipomed can only be obtained with a prescription and treatment should be started and maintained by a doctor who has experience in the treatment of patients with thalassaemia.
Ravi peab alustama ja läbi viima talasseemiaga patsientide ravis kogenud arst.
The active substance in Deferiprone Lipomed, deferiprone, is an iron chelator.
Ravimi Deferiprone Lipomed toimeaine deferiproon on rauda kelaativ aine.
Deferiprone Lipomed is used:
Ravimit Deferiprone Lipomed kasutatakse:
How has Deferiprone Lipomed been studied?
Kuidas ravimit Deferiprone Lipomed uuriti?
How is Deferiprone Lipomed used?
Kuidas ravimit Deferiprone Lipomed kasutatakse?
What are the benefits and risks of Deferiprone Lipomed?
Milles seisneb ravimi Deferiprone Lipomed kasulikkus ja mis riskid ravimiga kaasnevad?
* Withdrawal period (milk): - Zero hours after calving (when the dry period length is 32 days or more) - 4 days (8 milkings) after calving (when the dry period length is less than 32 days)
* Keeluaeg (piimale): - 0 tundi pärast poegimist (kui kinnisperioodi pikkus on 32 päeva või rohkem) - 4 päeva (8 lüpsikorda) pärast poegimist (kui kinnisperioodi pikkus on vähem kui 32 päeva)
Withdrawal period
Keeluaeg
EU/2/15/192/001 Velactis 1.12 mg/ml
1,12 mg/ml Süstelahus Veis (piimalehm)
Packaging Content Package size
Tugevus Ravimvorm Loomaliigid Manustamisviis Pakend Sisaldus Pakendi suurus
Annex A EU (MA) Number Invented name
Lisa A EL (ML)
Target species
5 viaali
1 April 2016
1. aprill 2016
More information on the orphan designation can be found here: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
Lisateave harvikravimiks nimetamise kohta on siin: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
What is Dropcys?
Mis on Dropcys?
Refusal of the marketing authorisation for Dropcys (mercaptamine hydrochloride) EMA/227275/2016
Dropcysi (merkaptamiinvesinikkloriid) müügiloa andmisest keeldumine EMA/227275/2016
After considering the grounds for this request, the CHMP re-examined the initial opinion and confirmed the refusal of the marketing authorisation on 1 April 2016.
Pärast taotluse põhjenduste arutamist vaatas inimravimite komitee oma algse arvamuse uuesti läbi ja kinnitas müügiloa andmisest keeldumist 1. aprillil 2016.
Although the role of mercaptamine eye drops in the treatment of corneal deposits appears sufficiently supported by the literature, current clinical recommendations and its routine use in hospital preparations, there were few data supporting the effectiveness of the concentration of mercaptamine used in Dropcys (0.1% solution).
Kuigi merkaptamiini sisaldavate silmatilkade roll sarvkesta ladestuste raviks näib olevat kirjanduse, kehtivate kliiniliste soovitustega ja rutiinse kasutamisega haiglapreparaatides piisavalt tõestatud, on Dropcysis kasutatava merkaptamiini kontsentratsiooni (0,1% lahus) efektiivsuse toetamiseks vähe andmeid.
What consequences does this refusal have for patients in clinical trials or compassionate use programmes?
Kuidas mõjutab keeldumine praegu kliinilistes uuringutes või eriloaga kasutamise programmides osalevaid patsiente?
The build-up of cystine crystals inside corneal cells can damage the eyes and cause serious vision problems.
Tsüstiini kristallide kogunemine sarvkesta rakkudesse võib kahjustada silmi ja põhjustada raskeid nägemisprobleeme.
The Committee confirmed the opinion that the effectiveness of Dropcys in the treatment of corneal deposits had not been sufficiently demonstrated and that there were unresolved issues regarding the formulation and long-term safety and sterility of the medicine.
Komitee kinnitas arvamust, et Dropcysi efektiivsus sarvkesta ladestuste ravis ei ole piisavalt tõendatud ning et seoses ravimi koostise ja ravimi pikaajalise ohutuse ja steriilsusega on lahendamata probleeme.
During the re-examination, the CHMP looked again at the data from the company.
Taasläbivaatamisel vaatas inimravimite komitee ettevõttelt saadud andmed uuesti läbi.
Therefore, the CHMP was of the opinion that the benefits of Dropcys did not outweigh its risks and recommended that it be refused marketing authorisation.
Inimravimite komitee oli seepärast arvamusel, et Dropcysi kasulikkus ei ole suurem kui sellega kaasnevad riskid, ja soovitas müügiloa andmisest keelduda.
The CHMP considered that the studies from the medical literature presented to support the application were insufficient.
Inimravimite komitee leidis, et taotluse toetuseks meditsiinikirjandusest esitatud uuringud on ebapiisavad.
In addition, the CHMP had concerns regarding other ingredients of the medicine, their impact on long-term safety, particularly in children, and how stable and sterile the solution would be once prepared.
Samuti pidas inimravimite komitee probleemiks ravimi teisi koostisaineid, nende mõju pikaajalisele ohutusele (eelkõige lastel) ning lahuse stabiilsust ja steriilsust pärast valmistamist.
Because mercaptamine has been used for many years to treat cystinosis and its use is well established, the applicant presented data from the medical literature to support its application for Dropcys.
Et merkaptamiini on kasutatud tsüstinoosi ravis palju aastaid ja selle kasutus on hästi tõestatud, esitas taotleja Dropcysi taotluse toetuseks meditsiinikirjanduse andmeid.
The active substance in Dropcys, mercaptamine hydrochloride, was expected to react with cystine to dissolve it and to form substances that could be removed from the cells.
Dropcysis toimeainena sisalduv merkaptamiinvesinikkloriid pidi eeldatavasti reageerima tsüstiiniga selle lahustamiseks ja moodustama aineid, mida saab rakkudest eemaldada.